Cenra Inc.

3716 · TW · Healthcare / Medical Distribution

32.15TWD-0.05 (-0.16%)

Price History

Full chart

Market Stats

Previous Close32.20

Open32.40

Day Range32.15 – 32.45

52-Week Range30.64 – 37.65

Volume190.05K

Market Cap4.98B

P/E (TTM)8.85

Forward P/E0.00

EPS3.83

Dividend Yield2.96%

Beta0.24

50-Day Avg34.19

200-Day Avg33.95

About

Cenra Inc. engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals. It provides CDMO services for internal and external partners; oral solids, injectables, specialty formulations, and APIs, supported by process development, scale-up, and regulatory support; oral solids, injectables, specialty formulations, and high-purity active pharmaceutical ingredients (APIs), supported by process development, scale-up, and regulatory support; distribution, and marketing for prescription drugs, OTC products, health supplements, personal care products, and medical devices;home care, caregiver training, and consulting for elderly support; develops and manufactures veterinary pharmaceuticals, and animal health products for livestock and companion animals and offers CDMO services for animal health partners. Cenra Inc. was founded in 2024 and is headquartered in Taipei, Taiwan.

Company Details

SectorHealthcare
IndustryMedical Distribution
CEOMr. Hou-Kai Wang
Employees0
HeadquartersNo. 23, Xiangyang Road, Taipei, Taiwan, 10046, Taiwan
Websitehttps://www.cenra.com

Leadership

Mr. Hou-Kai WangGeneral Manager & Director
Mr. Chih-Yung WuPresident
Chao-Lang LinDirector of Finance Department
Hui-Wen HsiaoAccounting Supervisor
Mr. Te-Feng ChaoDirector of Administrative Support Department
Mr. Teng-Pao LinChief Auditor
Mr. Yin-Nan SunVP, Deputy GM & President of Chunghwa Yuming Healthcare Co Ltd

Financials

Income Statement

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	7.95B	8.46B	8.57B	8.92B	8.57B
Growth (%)	-	+6.38%	+1.40%	+4.01%	-3.91%
Cost of Revenue	5.08B	5.37B	5.43B	5.51B	5.25B
Gross Profit	2.86B	3.09B	3.14B	3.41B	3.32B
Gross Margin	36.04%	36.51%	36.62%	38.20%	38.71%
Operating Expense	2.45B	2.72B	2.90B	3.11B	2.89B
Operating Income	411.36M	368.77M	238.67M	298.91M	428.14M
Operating Margin	5.18%	4.36%	2.78%	3.35%	5.00%
EBITDA	-	922.40M	765.02M	804.89M	828.05M
EBITDA Margin	-	10.91%	8.92%	9.02%	9.66%
Net Income	517.51M	477.54M	322.29M	317.35M	300.07M
Net Income Margin	6.51%	5.65%	3.76%	3.56%	3.50%
R&D	391.33M	435.73M	485.66M	501.36M	478.45M
R&D as % of Total Revenue	4.92%	5.15%	5.66%	5.62%	5.58%
Interest Expense	35.76M	41.88M	59.54M	64.30M	61.85M
Interest Expense % of Total Revenue	0.45%	0.50%	0.69%	0.72%	0.72%

Balance Sheet

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	12.79B	12.82B	12.86B	12.77B	12.45B
Total Liabilities	5.00B	5.39B	5.39B	5.22B	4.84B
Total Equity	7.75B	7.39B	7.43B	7.51B	7.57B
Cash	849.03M	438.00M	444.72M	588.01M	729.50M
Net Debt	1.92B	2.39B	2.64B	2.20B	1.90B

Cash Flow

Currency: TWD	2002-12-31	2008-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-	-	695.89M	167.27M	601.91M	750.55M	740.60M
Capital Expenditure	0	0	208.36M	270.97M	262.13M	318.99M	211.78M
Free Cash Flow	-	-	487.54M	-103.70M	339.78M	431.56M	528.81M
Dividends Paid	-	-	298.08M	268.27M	238.47M	149.04M	148.93M
FCF to OCF	-	-	70.06%	-62.00%	56.45%	57.50%	71.40%
Dividend Paid to FCF	-	-	61.14%	-258.70%	70.18%	34.54%	28.16%

Key Statistics & Ratios

Market Cap4.98B

Enterprise Value7.06B

Trailing P/E8.85

Forward P/E0.00

Price / Sales0.59

Price / Book0.65

EPS3.83

Book Value52.65

Revenue (TTM)8.44B

Gross Profit (TTM)3.30B

EBITDA759.25M

Profit Margin6.05%

Operating Margin4.12%

Return on Equity6.76%

Return on Assets2.35%

Shares Outstanding146.83M

Shares Float96.44M

Beta0.24

Dividend Yield2.96%

Dividend Rate1.00

Payout Ratio26.56%

Dividends

20261×

1.00Jul 23, 2026

20251×

1.02Jul 24, 2025